NEW DELHI (Reuters) – India’s only domestically developed COVID-19 vaccine, Covaxin, has been found to be 78% effective in a second analysis of clinical trials done around the country, its makers said https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf on Wednesday.
“I am very pleased to state that Covaxin … has shown the efficacy of 78% in the second interim analysis,” said Balram Bhargava, the chief of the state-run Indian Council of Medical Research that has created the vaccine with Bharat Biotech.
The first analysis released in March had shown an efficacy rate of 81%.
(Reporting by Krishna N. Das; Editing by Hugh Lawson)
